Online BusinessBharat Biotech's 'INDIRAB' vaccine sales doubles
Bharat Biotech, a leading manufacturer of vaccines and biotherapeutics, expects its Anti-Rabies vaccine INDIRAB to more than double its sales within the next two years as sales crossed the one crore doses sales mark.
- Konark Knowledge Park to have biotech incubation centre - Bharat Biotech secures patent for Lysostaphin - Bharat Biotech gets patent for Lysostaphin - Bharat Biotech to test swine flu vaccine in 2 months - Suven Life"s drug discovery achieves milestone - FDC closes buy-back offer; promoters" stake rises to 65.76%
With demand for its vaccine from public health organisations, government ministries of health in the domestic market in over 30 countries, the company expects the sales to soar further.
Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech International, said Bharat Biotech"s vaccine manufacturing methods are best suited to meet growing demand for novel, cost effective vaccies.
"We believe that our 3rd generation rabies Vero cell-based vaccine produced using chromatographically purified manufacturing process offers not just lower costs but also a highly purified vaccine with minimal side effects," he said.
Bharat Biotech continues to make new investments to expand its production fcilities at its Hyderabad plant to meet the rising demand for rabies vaccine both in the domestic and international markets. The capacity expansion will also help meet the requirements from new vaccine development programs the company has in the pipeline, Ella said.
INDIRAB is said to be one of the first chromatographically purified Vero Cell Rabies Vaccine ever made and has been developed from virus strains obtained from CDC (Centre"s for Disease Control & Prevention), Atlanta, USA.
The vaccine is free from inapparent viruses and adventitious agents capable of causing tumors.
INDIRAB is also safe with no chance of egg protein allergy, antibiotic allergy and bird flu transmission, seen with chick and duck embryo rabies vaccines.